skip to primary navigationskip to content

Richard Baird

Dr Richard BairdJean Abraham


Research Interests

1. Early phase clinical trials, including expertise in:

  • first-in-human studies & drug combination trials
  • new small molecule & antibody therapeutics
  • development of pharmacodynamic and predictive biomarkers
  • novel clinical trial designs including Bayesian / adaptive approaches

2. Focus on breast cancer therapeutics.

3. Investigator-initiated clinical trials funded by: 

  • Cancer Research UK 
  • Brain Tumour Charity 
  • EU Framework 7 (RATHER consortium, EUROCAN platform)
  • AntiCancer Fund
  • AstraZeneca 
  • Boehringer-Ingelheim
  • Genentech
  • Medimmune


Pubmed journal articles - pubmed

Key publications

Sharma RA, Plummer R, Stock J, Greenhalgh T, Ataman O, Kelly S, Clay R, Adams R, Baird RD, et al. Clinical development of new drug–radiotherapy combinations. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.79 (2016).

Ang JE, Pandher R, Ang JC, Asad Y, Henley AT, Valenti M, Box G, de Haven Brandon A, Baird RD, Friedman L, et al. Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation. Mol. Cancer Ther. 15, 1412–1424 (2016).

Baird RD, et al. An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. Ecancermedicalscience 10, 1–58 (2016).

Baird RD & Carroll JS. Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications. Clin. Oncol. 28, 1–3 (2016).

Wason JMS, Abraham JE, Baird RD, et al. A Bayesian adaptive design for biomarker trials with linked treatments. Br. J. Cancer 113, 699–705 (2015).

Spicer JF, Baird RD, et al. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. Eur. J. Cancer 51, 137–145 (2015).

Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, et al. Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. Clin. Cancer Res. 21, 739–748 (2014).

Sarker D, Ang J, Baird RD, et al. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 21, 77–86 (2014).

Baird RD & Caldas C. Genetic heterogeneity in breast cancer: the road to personalized medicine? BMC Medicine 11 (1), 151 (2013).

Sandhu, S.K., Schelman, W.R., Wilding, G., Moreno, V., Baird RD, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncology 2045 (13), 882-892 (2013).

Venugopal B*, Baird RD*, et al. A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research 19 (15), 4262-4272 (2013).

Olmos D*, Baird RD*, Yap T, Papadatos-Pastos D, Sandhu S, Massard C, De Bono JS. Addition of baseline circulating tumour cell count improves the Royal Marsden Hospital prognostic score to select patients for oncology phase 1 trials. Clinical Cancer Research 17(15):5188-96 (2011).

Baird RD, Planting A, Reid AHM, Kitzen J, de las Heras B, Eskens F, de Bono JS, Workman P, Verweij J (2009). A phase 1 dose escalation, pharmacokinetic and pharmacogenomic study of ES-285, a novel marine cytotoxic agent, administered as an intravenous infusion over 24h every 21 days in patients with advanced solid tumours. Molecular Cancer Therapeutics 8(6): 1430-1437

(* = joint first author)